Innovative Therapeutics ReNetX Bio focuses on developing first-in-class therapies for central nervous system injuries and conditions, presenting opportunities to collaborate with healthcare providers and biotech firms seeking advanced neuroscience solutions.
Growth Potential With recent recognition such as being named Innovator of the Month and receiving industry awards, ReNetX demonstrates momentum that can be leveraged to attract strategic partners and investors interested in breakthrough CNS treatments.
Funding & Development Having secured $2.8M in funding and progressing toward Phase 2 trials for AXER-204, the company offers opportunities for service providers, equipment suppliers, and clinical research organizations to support their expanding R&D efforts.
Niche Market Focus Targeting niche markets such as spinal cord injury and traumatic brain injury, ReNetX’s specialized focus opens avenues for companies in neurorehabilitation, medical devices, and neuroprotective therapies to align their offerings.
Small but Agile With a lean team of 2-10 employees and a clear R&D mission, ReNetX is positioned as an agile partner for customized biotech solutions, contract research, or collaborative innovation ventures to accelerate their development pipeline.
$100M$250M
$25M$50M
$250M$500M
$1M$10M
$250M$500M
$1M$10M
$1M
$10M$25M
$1MReNetX Bio uses 8 technology products and services including Snowplow, Weebly, Google Fonts API, and more. Explore ReNetX Bio's tech stack below.
| ReNetX Bio Email Formats | Percentage |
| FLast@renetx.com | 50% |
| FLast@renetx.com | 50% |
Biotechnology ResearchConnecticut, United States2-10 Employees
Our mission is to provide first-in-class therapeutics to treat injury/damage to the central nervous system (CNS) in conditions such as spinal cord injury (SCI), glaucoma, and traumatic brain injury. Our treatment, AXER-204, hopes to rebuild connections between healthy and damaged neurons through the blocking of receptors that naturally inhibit axonal growth. We are currently approaching Phase 2 of testing.
Company Overview
Funding & FinancialsReNetX Bio has raised a total of $2.8M of funding over 3 rounds. Their latest funding round was raised on Sep 28, 2020 in the amount of $2.8M.
ReNetX Bio's revenue is estimated to be in the range of $1M
Funding & FinancialsReNetX Bio has raised a total of $2.8M of funding over 3 rounds. Their latest funding round was raised on Sep 28, 2020 in the amount of $2.8M.
ReNetX Bio's revenue is estimated to be in the range of $1M
1-888-653-2347 
support@leadiq.com